Thermo Fisher Scientific NY-BR-1 Monoclonal Antibody (NY-BR-1 No. 2)

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Immunohistochemistry (Paraffin) (IHC (P))

1:100

-

Immunohistochemistry (Frozen) (IHC (F))

1:100

-

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

NY-BR-1 No. 2

Immunogen

A 77 aa peptide from human NYBR-1 protein if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:NY-BR-1,uniProtId:Q9BXX3-1,ncbiNodeId:9606,antigenRange:77,antigenLength:1397,antigenImageFileName:MA5-12645_NY-BR-1_Q9BXX3-1_House_mouse.svg,antigenImageFileNamePDP:MA5-12645_NY-BR-1_Q9BXX3-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.2 mg/mL

Purification

Protein G

Storage buffer

PBS, pH 7.4, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_10977217

Product Specific Information

MA5-12645 targets NY-BR-1 in IHC (P, F) applications and shows reactivity with Human samples.

The MA5-12645 immunogen is a 77 aa peptide from human NYBR-1 protein.

Target Information

NY-BR-1 is a novel differentiation marker predominantly expressed in normal breast and breast cancer. It has been shown by Immunohistochemistry (IHC) that NY-BR-1 was present solely in ductal epithelium of normal breast tissue. Invasive carcinoma of the breast and carcinoma in situ were positive for NY-BR-1, whereas most other tumors and normal tissues are negative, with the exceptions of one-third of sweat gland carcinomas and around two percent of prostate carcinoma. NY-BR-1 is reported to express more frequently in estrogen-positive and lymph node-negative primary carcinomas, and more commonly in grade 1 than in grade 2 or grade 3. In a study by Varga et al (2006) forty-nine percent of lymph node metastasis were shown to be positive.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.